Biostem Technologies Inc
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wou… Read more
Biostem Technologies Inc (BSEM) - Net Assets
Latest net assets as of September 2025: $50.02 Million USD
Based on the latest financial reports, Biostem Technologies Inc (BSEM) has net assets worth $50.02 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($62.39 Million) and total liabilities ($12.38 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $50.02 Million |
| % of Total Assets | 80.16% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | 2385.55% |
| Growth Volatility | 218.73 |
Biostem Technologies Inc - Net Assets Trend (1999–2024)
This chart illustrates how Biostem Technologies Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Biostem Technologies Inc (1999–2024)
The table below shows the annual net assets of Biostem Technologies Inc from 1999 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $40.88 Million | +4255.39% |
| 2023-12-31 | $-983.67K | +75.10% |
| 2022-12-31 | $-3.95 Million | +31.83% |
| 2021-12-31 | $-5.79 Million | -2.86% |
| 2020-12-31 | $-5.63 Million | -43.09% |
| 2019-12-31 | $-3.94 Million | -135.40% |
| 2018-12-31 | $-1.67 Million | -214.27% |
| 2017-12-31 | $1.46 Million | +204.20% |
| 2016-12-31 | $481.08K | -70.75% |
| 2015-12-31 | $1.64 Million | +339.91% |
| 2014-12-31 | $373.83K | +119.73% |
| 1999-12-31 | $-1.89 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Biostem Technologies Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 412055700.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $54.62 Million | 133.61% |
| Total Equity | $40.88 Million | 100.00% |
Biostem Technologies Inc Competitors by Market Cap
The table below lists competitors of Biostem Technologies Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Life & Banc Split Corp
TO:LBS
|
$77.56K |
|
TAKYX
NMFQS:TAKYX
|
$77.57K |
|
HARMONIC (HMC.SG)
STU:HMC
|
$77.67K |
|
KEPPEL (KEP1.SG)
STU:KEP1
|
$77.78K |
|
BIYT39
SA:BIYT39
|
$77.55K |
|
Millennium Food-Tech LP
TA:MIFT
|
$77.45K |
|
PARROT (P2W.SG)
STU:P2W
|
$77.44K |
|
Applied Nutrition Plc
LSE:APN
|
$77.41K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Biostem Technologies Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -983,675 to 40,875,532, a change of 41,859,207.
- Net income of 31,884,321 contributed positively to equity growth.
- Share repurchases of 1 reduced equity.
- Other factors increased equity by 9,974,887.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $31.88 Million | +78.0% |
| Share Repurchases | $1.00 | -0.0% |
| Other Changes | $9.97 Million | +24.4% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Biostem Technologies Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.38x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.00 | $8.29 | x |
| 2015-12-31 | $0.00 | $8.29 | x |
| 2016-12-31 | $0.00 | $8.29 | x |
| 2017-12-31 | $0.00 | $8.29 | x |
| 2020-12-31 | $-0.63 | $8.29 | x |
| 2022-12-31 | $-0.34 | $8.29 | x |
| 2023-12-31 | $-0.06 | $8.29 | x |
| 2024-12-31 | $2.46 | $8.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Biostem Technologies Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 78.00%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.56%
- • Asset Turnover: 2.15x
- • Equity Multiplier: 3.43x
- Recent ROE (78.00%) is above the historical average (-85.64%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1999 | 0.00% | -616.79% | 0.22x | 0.00x | $-7.95 Million |
| 2009 | -3.16% | -27.71% | 0.11x | 1.00x | $-269.10K |
| 2010 | -8.84% | -18.88% | 0.47x | 1.00x | $-507.83K |
| 2011 | -15.17% | -38.66% | 0.39x | 1.00x | $-874.58K |
| 2014 | -49.92% | 0.00% | 0.00x | 1.18x | $-223.43K |
| 2015 | -144.84% | -1570.88% | 0.05x | 1.79x | $-2.54 Million |
| 2016 | -815.47% | -651.81% | 0.22x | 5.64x | $-4.01 Million |
| 2017 | -325.15% | -1473.67% | 0.11x | 2.04x | $-4.99 Million |
| 2018 | 0.00% | -746.66% | 0.24x | 0.00x | $-7.43 Million |
| 2019 | 0.00% | -240.85% | 0.83x | 0.00x | $-5.93 Million |
| 2020 | 0.00% | -94.75% | 0.95x | 0.00x | $-1.81 Million |
| 2021 | 0.00% | -33.30% | 1.62x | 0.00x | $-849.44K |
| 2022 | 0.00% | -102.90% | 1.98x | 0.00x | $-6.67 Million |
| 2023 | 0.00% | -50.84% | 1.15x | 0.00x | $-8.38 Million |
| 2024 | 78.00% | 10.56% | 2.15x | 3.43x | $27.80 Million |
Industry Comparison
This section compares Biostem Technologies Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Biostem Technologies Inc (BSEM) | $50.02 Million | 0.00% | 0.25x | $77.55K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |